

Association of Systemic Immune-inflammation Index With Short-Term Mortality of Congestive Heart Failure: A Retrospective Cohort Study

1 Yiyang Tang¹, Xiaofang Zeng¹, Yilu Feng¹, Qin Chen¹, Zhenghui Liu², Hui Luo³, Lihuang
2 Zha^{1*} and Zaixin Yu^{1,4*}

3 ¹ Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, People's
4 Republic of China

5 ² Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, People's
6 Republic of China

7 ³ Department of Cardiovascular Medicine, the First Hospital of Changsha, Changsha, Hunan,
8 People's Republic of China

9 ⁴ National Clinical Research Center for Geriatric Disorders (Xiang Ya), Changsha, Hunan, People's
10 Republic of China

11 * Correspondence:

12 Zaixin Yu
13 yuzaixin@126.com

14 Lihuang Zha
15 zhali Huang@csu.edu.cn

16 **Keywords:** congestive heart failure¹, systemic immune-inflammation index², mortality³,
17 biomarker⁴, MIMIC-III⁵.

18 Abstract

19 **Purpose:** The present study aimed to clarify the potential predictive significance of Systemic
20 immune-inflammation index (SII) in assessing the poor prognosis of critically ill patients with
21 congestive heart failure (CHF).

22 **Methods:** Detailed clinical data were extracted from the Multiparameter Intelligent Monitoring in
23 Intensive Care III database after gaining access and building the local platform. The 30- and 90-day
24 and hospital all-cause mortalities of the patient was the primary outcome, and the readmission rate
25 and the occurrence of major cardiovascular adverse events (MACEs) were the secondary outcomes.
26 the Cox proportional hazard model and Logistic regression analysis were selected to reveal the
27 relationship between SII level and the research outcome. Further, the propensity score matching
28 (PSM) analysis was performed to improve the reliability of results by reducing the imbalance across
29 groups.

30 **Results:** There were a total of 4606 subjects who passed the screening process and entered the
31 subsequent analysis. Multivariate regression analysis showed that after adjusting for possible
32 confounders, including age, heart rate, and albumin, etc., the high level of SII was independently
33 associated with 30- and 90-day and hospital mortalities (tertile 3 versus tertile 1: HR, 95% CIs: 1.23,
34 1.04-1.45; 1.21, 1.06-1.39; 1.26, 1.05-1.50) and the incidence of MACEs (tertile 3 versus tertile 1:
35 OR, 95% CI: 1.39, 1.12-1.73) in critically ill patients with CHF, but no significant correlation was

36 found between SII and the readmission rate. Consistently, patients with high SII level still presented
37 a significantly higher short-term mortality than patients with low SII in the PSM subset.

38 **Conclusion:** In critically ill patients with CHF, high level of SII could effectively predict high 30-
39 and 90-day and hospital mortalities, as well as the high risk of occurrence of MACEs.

40 **1 Introduction**

41 Congestive heart failure (CHF) is defined as a pathological condition in which the cardiac output is
42 insufficient to maintain the perfusion and metabolic needs of various tissues and organs, mainly
43 characterized by the congestion of pulmonary circulation, accompanied by the corresponding clinical
44 manifestations such as shortness of breath and decreased activity tolerance(Sun et al., 2020). CHF is
45 the severe or terminal stage of most primary cardiovascular diseases and has increasingly become a
46 major public problem threatening human health. In the United States and Europe, more than 1
47 million heart failure patients are hospitalized each year, and as the population ages, this number is
48 expected to increase by more than 50% in the next 15 years(Povsic, 2018). In addition, although
49 some progress has been made in the treatment in recent years, the prognosis of CHF patients is still
50 poor, with 5-year mortality rate as high as 40-50%(Chen et al., 2011). Therefore, accurate assessment
51 and stratification of prognosis are critical to the clinical management of CHF, and the development of
52 certain prognostic-related biomarkers is also pressing, which can help clinicians to identify high-risk
53 patients early and take more aggressive treatment measures(Xu et al., 2021).

54 Although the specific pathogenesis of heart failure remains unclear, abnormal immune activation and
55 chronic inflammation play an important role. The damage, repair and remodeling of myocardium are
56 the important link in the occurrence and development of heart failure, of which
57 immune/inflammatory cells (neutrophils, lymphocytes, etc.) and the inflammatory factors (tumor
58 necrosis factor, interleukin-6, etc.) released by them are involved(Li et al., 2021). Inflammatory
59 factors can induce cardiomyocyte hypertrophy, apoptosis and fibrosis, and ultimately lead to adverse
60 cardiac remodeling and progressive left ventricular dysfunction(Bradham et al., 2002). Inflammatory
61 factors have been considered to be biomarkers for poor prognosis of heart failure, and anti-
62 inflammatory therapy is also expected to become a new target for the treatment of heart
63 failure(Mann, 2015).

64 Systemic immune-inflammation index (SII) is a composite inflammatory indicator that combines
65 three significant immune cells, including neutrophil, lymphocyte, and platelet, and is considered to
66 be an excellent indicator of local immune response and systemic inflammation(Wang et al., 2016).
67 Neutrophils, platelets and the cytokines they produce are mainly related to non-specific immune
68 responses, while lymphocytes are considered to be mainly related to specific immune pathways.
69 Compared with the absolute count of single immune cells, SII has a better representation in reflecting
70 the inflammation status of the body, with better stability. Until now, SII has been confirmed to be
71 closely correlated with the poor prognosis of a variety of cardiovascular diseases, including coronary
72 artery disease(Yang et al., 2020), aortic stenosis(Tosu et al., 2021), infective endocarditis(Agus et al.,
73 2020), etc., showing good application prospects, but no studies have shown that SII is correlated with
74 the prognosis of patients with CHF. In view of this, the present study attempted to elucidate the
75 independent association between SII and the occurrence of adverse events such as short-term
76 mortality in critically ill patients with CHF, so as to provide reference for the prevention and
77 treatment of heart failure.

78 **2 Materials and Methods**

79 **2.1 Data Sources**

80 All data used in the research and analysis of this study are derived from MIMIC-III (Medical
81 Information Mart for Intensive Care III) database, a free and open-access large-scale critical care
82 medicine database developed and run by the Massachusetts Institute of Technology for researchers
83 all over the world. Another advantage of this database, in addition to including the detailed clinical
84 data such as demographic data, vital signs, laboratory tests, and various treatment information, is that
85 it provides accurate death information of all subjects, including time of death in the hospital or within
86 90 days after discharge, which makes it possible for the clinicians to carry out the prognostic related
87 research. Besides, since this database has been approved by the local ethics committee as a whole and
88 the individual identifying information of the research subjects has been deleted, this study no longer
89 needs additional ethical approval.

90 **2.2 Population Selection and Exclusion**

91 The subjects of this study are all from the MIMIC-III database(Johnson et al., 2016), and patients
92 who meet all the following requirements are included in the subsequent analysis: (1) Patients
93 diagnosed with CHF based on the ICD-9 code (code 428.0); (2) Adult patients 18 years of age and
94 older; (3) First admission to ICU. Patients who met one of the following criteria were excluded from
95 the study: (1) The length of ICU stay was shorter than 24 hours; (2) Absence of SII results during
96 hospitalization; (3) Survival time was less than 0 (the time of death of some organ donors may be
97 earlier than the admission).

98 **2.3 Study Outcomes**

99 The short-term mortality, including the 30- and 90-day and hospital all-cause mortalities of critically
100 ill patients with CHF, were selected as the primary study outcome, while the secondary study
101 outcome events were defined as the patients' readmission rate and the occurrence of major adverse
102 cardiac events (MACEs), which is a composite outcome event, including all-cause death,
103 readmission for acute heart failure, the use of mechanical circulatory support and the implementation
104 of heart transplantation(Li et al., 2020).

105 **2.4 Data Extraction and Integration**

106 Through the PostgreSQL software (version 9.6, <https://www.postgresql.org/>), we extracted detailed
107 clinical data of the research subjects from the MIMIC-III database, including demographic data (age,
108 gender, race, etc.), comorbidities (hypertension, diabetes mellitus, atrial fibrillation, etc.), vital signs
109 (heart rate, blood pressure, respiratory rate, etc.), severity of illness scores (SOFA and SAPSII
110 scores), laboratory tests (blood routine, electrolytes, etc.) and intervention measures (dialysis,
111 mechanical ventilation, etc.). And the value of SII is equal to the product of the platelet count and the
112 neutrophil count divided by the lymphocyte count(Hu et al., 2014).

113 After separately extracting the required tables from the MIMIC-III database, the Stata software
114 (version 16, <https://www.stata.com/>) was used to process and merge these original table and generate
115 a complete table that can be used for subsequent analysis. Use the "winsorize" function to identify
116 and process outliers, and fill in missing values through multiple compensation methods.

117 **2.5 Statistical Analyses**

118 The continuous variables were presented in the form of mean \pm standard deviation (SD) or median
119 (interquartile range). If continuous variables satisfy both normal distribution and homogeneity of

120 variance, t-test was used for analysis, while the Mann-Whitney U test was conducted if the normal
121 distribution or homogeneity of variance were not satisfied. Categorical variables are expressed in the
122 form of the number of cases (percentage), with the chi-square test (or Fisher's exact method) for
123 analysis.

124 We constructed a generalized additive model (GAM) to determine the non-linear relationship
125 between SII and 30- and 90-day all-cause mortalities in critically ill patients with CHF. In addition,
126 we also visually show the relationship between SII and patients' survival through the Kaplan-Meier
127 (K-M) curve, and use the Log-rank test for hypothesis testing.

128 In order to relieve the interference of possible confounding factors on the results, we completed
129 univariate and multivariate regression analysis to further clarify the relationship between SII and
130 outcome variables. In the crude model, no variables were adjusted. In model I, the age, gender, and
131 race variables were adjusted, while model II further adjusted other 13 variables on the basis of these
132 variables of model II, including heart rate, blood urea nitrogen (BUN), albumin, troponin T (cTnT),
133 N-terminal probrain natriuretic peptide (NT-proBNP), urine output of first day, cardiac index, the
134 type of first ICU admission, the use of mechanical ventilation and vasopressor, pneumonia, and liver
135 diseases. The selection of confounding factors follows the following principles(Jaddoe et al., 2014):
136 (1) A certain factor has an influence of more than 10% on the research variable; (2) Some factors
137 may have a significant impact on the outcome variable based on past experience. Besides, we used
138 the variance inflation factor (VIF) to test the multicollinearity between variables with 5 as the
139 threshold, and the variables with a high degree of collinearity, serum chloride, were deleted to avoid
140 over-fitting of the model. The Cox regression analysis was used to determine the relationship
141 between SII and short-term mortalities in critically ill patients with CHF, while Logistic regression
142 analysis was used to analyze the association between SII and readmission rates or MACEs.

143 To further enhance the credibility of our analysis, we performed the subgroup analysis and
144 propensity score matching (PSM) analysis. First, By the subgroup analysis, determine whether the
145 correlation between the SII and the high 30-day all-cause mortality in critically ill patients with CHF
146 was consistent across various subgroups stratified mainly by comorbidities, and reflect the stability of
147 SII as a prognostic marker. The optimal cut-off value of SII for the short-term mortality was
148 determined by the X-tile (version 3.6.1, Yale University School of Medicine) software, and then the
149 entire study population was divided into two groups, namely the high SII group and the low SII
150 group. In this study, all variables with uneven distribution between the two groups of patients were
151 included in the PSM model as covariates, and the corresponding propensity score was calculated by
152 Logistic regression. Then the two groups of individuals with similar propensity scores were matched
153 by 1:1 using nearest neighbor matching method with a caliper width of 0.05, and the histogram of the
154 propensity score distribution was draw, which was carried out through the Stata software. Then, K-M
155 curves were depicted and Cox regression analysis was conducted in the matching cohort after PSM,
156 which further validated SII as an independent risk factor for poor prognosis in the critically ill
157 patients with CHF.

158 The statistical analysis above was conducted by EmpowerStats software (version 2.20,
159 <http://www.empowerstats.com/cn/>, X&Y solutions, Inc, Boston, MA) and R software (version 3.4.3).
160 $p < 0.05$ (two-sided) was considered statistically significant.

161 **3 Results**

162 **3.1 Clinical Characteristics of Study Subjects**

163 The study subjects were screened according to the process mentioned above, and 4606 subjects were
164 finally included. The demographic data, vital signs, comorbidities, treatment, scores and laboratory
165 examinations and other relevant information are shown in Table 1 in detail. In general, the study
166 subjects included were a little old, with a median age of 74.91 years old, mainly male patients,
167 reaching 2436, accounting for 52.89%. And the majority of the subjects were whites, accounting for
168 72.71%, blacks only 7.21%, and other races including Asians accounted for 20.08%. The duration of
169 follow-up was 90 days, of which 3226 survived and 1380 died due to various reasons before the end
170 of the study. SII (213.97 vs 163.11, $p < 0.001$) was significantly higher in the non-survivor cohort.
171 Compared with the survivor group, older patients were identified more frequently in the non-survivor
172 group, with more unstable vital signs, higher incidence of comorbidities such as VHD, atrial
173 fibrillation, and renal failure, as well as higher SOFA and SAPSII scores.

174 **3.2 SII Distinguishing a Poor Short-term Prognosis**

175 GAM analysis was used to identify the non-linear correlation between SII and the short-term all-
176 cause mortality of patients, which showed that there was a U-shaped curve relationship between SII
177 and 30-day (Figure 1A) and 90-day (Figure 1B) all-cause mortalities in critically ill patients with
178 CHF, indicating that higher or lower SII may be associated with increased mortality. The K-M
179 survival curve (Figure 2) also showed that compared with the low SII group, patients with high SII
180 level had a lower overall survival rate and shorter survival time, with a statistically significant p
181 value.

182 In order to verify the independent relationship between SII and the poor short-term mortality of CHF
183 patients, we performed the univariate and multivariate Cox regression analysis (Table 2), with SII
184 stratified by tertiles. In crude model, the third tertile of SII increased significantly the risk of 30- (HR,
185 95% CI: 1.73, 1.48-2.03) and 90-day (HR, 95% CI: 1.65, 1.45-1.88) and hospital (HR, 95% CI: 1.61,
186 1.36-1.91) all-cause mortalities compared with the first tertile. In multivariate model I, after adjusting
187 for age, sex, and race, the third tertile of SII group also suffered from the higher risk of 30- (HR, 95%
188 CI: 1.63, 1.40-1.91) and 90-day (HR, 95% CI: 1.57, 1.38-1.79) and hospital (HR, 95% CI: 1.45, 1.22-
189 1.72) all-cause mortalities. In model II, in addition to adjusting for the variables in model I and other
190 possible confounders such as pneumonia, the use of dialysis, and BUN level, high levels of SII were
191 still strongly associated with poor 30- (HR, 95% CI: 1.23, 1.04-1.45) and 90-day (HR, 95% CI: 1.21,
192 1.06-1.39) and hospital (HR, 95% CI: 1.26, 1.05-1.50) all-cause mortalities.

193 **3.3 Association between SII and Readmission and MACEs**

194 For MACEs, a similar trend was observed. In model II (Table 3), patients with an $SII \geq 2730.11$ were
195 still at higher incidence of MACEs (OR, 95% CI: 1.39, 1.12-1.73). However, in the multivariate
196 regression analysis, there was no obvious independent correlation between SII and readmission rate
197 in the critically ill patients with CHF (tertile 3 versus tertile 1: OR, 95% CI: 0.97, 0.81-1.15).

198 **3.4 Subgroup Analyses**

199 The subgroup analysis was conducted to reveal the correlation between SII and 30-day mortality
200 across comorbidities and different parameters, and the results were shown in Table 4. First, the
201 results of the study showed that in all subgroups, the increase in SII level was closely related to the
202 increase in the 30-day all-cause mortality of critically ill patients with CHF. Besides, most of the
203 stratification factors have not been found to have a significant impact on the relationship between the
204 SII and 30-day all-cause mortality (interaction p value > 0.05), except for hyperlipemia ($p = 0.006$) and
205 acute myocardial infarction (AMI, $p = 0.016$).

206 **3.5 Prognostic Value of SII After PSM**

207 Determine the optimal cut-off value of SII for 90-day all-cause mortality of critically ill patients with
208 CHF through X-tile software, which is 5533.4. Subjects were divided into two groups according to
209 the cut-off value, and their clinical characteristics were summarized in Table 5, most of which were
210 unevenly distributed across the two groups. In order to effectively balance these confounding factors
211 and improve the credibility of our results, we conducted a PSM analysis with 1:1 matching. After
212 PSM, 602 pairs of research objects were generated and the difference of almost all variables were
213 balanced between the two groups, with a good matching performance (Figure 3). At the same time,
214 after PSM, compared with the low SII level group, subjects in the high SII level group still
215 underwent higher 30- (24.9% vs 33.2%, $p=0.002$) and 90-day (35.0% vs 42.0%, $p=0.013$) and
216 hospital (22.4% vs 27.7%, $p=0.033$) all-cause mortalities, with shorter survival time (Table 5 and
217 Figure 4). Besides, after adjusting for these covariable in the model II, the increased SII was also
218 associated with increased risk of short-term all-cause mortality in critically ill patients with CHF after
219 PSM and the results were shown in Figure 5 in the form of a forest map.

220 **4 Discussion**

221 CHF is widespread all over the world, with gradually increasing incidence with age, and has become
222 one of the diseases with the highest rates of hospitalizations and deaths in the world, bringing about
223 enormous medical expenditure and social burden, especially in developing countries(Savarese and
224 Lund, 2017). In addition to exploring promising treatments, the development of novel prognostic
225 markers for risk stratification of patients is also of great value for improving the prognosis of
226 patients. As we all know, as a commonly used indicator of heart failure, NT-proBNP can make a
227 good performance in prognostic evaluation. However, the clinical applications of NT-proBNP for
228 risk assessment has some drawbacks and problems. First, compared to the real value, the detection of
229 NT-proBNP tend to be underestimated because of the short half-life. Moreover, the test of NT-
230 proBNP may be affected by various factors such as age, gender, and kits(Cho et al., 2020). Therefore,
231 the search for more possible biomarkers has gradually attracted the attention of researchers and
232 clinicians.

233 In the present study, we extracted the clinical data of 4606 critically ill patients who diagnosed with
234 CHF between 2001 and 2012 in MIMIC-III database, and analyzed the relationship between SII and
235 short-term prognosis by univariate and multivariate regression analyses for the first time. And the
236 results have verified that SII could be an independent biomarker for poor short-term prognosis of
237 CHF. There was a nonlinear relationship between SII and 30- and 90-day mortalities. And the higher
238 SII level, the higher risk of 30- and 90-day and hospital mortalities, as well as the higher incidence of
239 MACEs. The correlation remained significant after adjusting for possible confounders, stratifying
240 according to comorbidities, and PSM matching, respectively.

241 Inflammation, a widely accepted hallmark of heart failure, has been proven to play an indispensable
242 role in the pathogenesis of heart failure(Dick and Epelman, 2016). The increase and activation of
243 inflammation-related cytokines not only present a reflection of the activation of inflammation in
244 vivo, but have also been identified as being associated with poor prognosis in heart failure. Tumor
245 necrosis factor α (TNF- α) was the first cytokine found to be significantly elevated in the serum of
246 patients with heart failure, which could directly induce myocardial apoptosis and necrosis, bringing
247 about ventricular adverse remodeling(Anker and von Haehling, 2004). The elevated levels of TNF- α
248 often indicated impaired cardiac systolic function and poor long-term survival(Rauchhaus et al.,
249 2000). In addition, interleukin 6 (IL-6), another classic cytokine mainly derived from monocytes,

250 could be significantly increased in patients with left ventricular systolic dysfunction without clinical
251 symptoms, and may be a sensitive indicator for the early diagnosis of heart failure(Plenz et al., 2001).
252 IL-6 was also positively correlated with the severity of heart failure, the concentration of which was
253 negatively correlated with left ventricular ejection fraction and overall survival(Markousis-
254 Mavrogenis et al., 2019). Although these inflammatory molecules had good performance in the
255 prognostic evaluation of patients, the expensive detection cost limited their clinical application. As a
256 novel biomarker, SII can systematically and comprehensively reflect the status of inflammation in
257 vivo. Blood routine is a routine examination for almost all hospitalized patients. It is simple, fast, and
258 inexpensive. Compared with NT-proBNP, cytokines and other prognostic indicators, SII can
259 effectively screen high-risk patients, guide the formulation of individualized treatment plans and
260 improve the prognosis of patients without additional cost, with a broad application prospect,
261 especially in underdeveloped areas.

262 The mechanisms of the relationship between SII and adverse prognosis of CHF remains unclear, and
263 possible explanations are as follows. Recently, it has been revealed that circulating immune cells and
264 their subtypes had a vital indicative effect on the prognosis of cardiovascular diseases(Strassheim et
265 al., 2019). SII was a prognostic indicator that integrates three circulating immune cells, including
266 neutrophils, lymphocytes, and platelets, the increase of which indicates either a relative increase in
267 platelets and neutrophils counts or a relative decrease in lymphocytes. Neutrophils are the main
268 component of white blood cells, accounting for 60-70% of the total, and play an important role in the
269 non-specific immune system. In the inflammatory response, neutrophils react rapidly, with strong
270 chemotaxis and phagocytosis, and participate in the progression of various cardiovascular diseases,
271 including heart failure(Bonaventura et al., 2019). In addition, neutrophils could contribute to
272 oxidative stress and endothelial dysfunction by releasing a large amount of myeloperoxidase,
273 NADPH oxidase, and so on(Swirski and Nahrendorf, 2013). According to a community-based
274 study(Arruda-Olson et al., 2009), absolute neutrophils can effectively predict the increased incidence
275 of acute decompensated heart failure after AMI, and it was also an independent risk factor for
276 death(Uthamalingam et al., 2011). Lymphocytes mainly consist of two subtype including T and B
277 cells, which were often associated with the specific immunity. Several previous studies have reported
278 that lymphocyte counts in patients with heart failure were lower than in the normal population and
279 lymphopenia served as an independent predictor of poor survival of patients with chronic and
280 advanced heart failure(Charach et al., 2011; Vaduganathan et al., 2012). Lymphopenia was
281 considered to be an important feature of systemic inflammation, which may be caused by the
282 following mechanisms. First, the circulating lymphocytes were attracted into the cardiac tissue,
283 leading to its redistribution. Then, lymphopenia was related to the activation of renin-angiotensin-
284 aldosterone hormone and the adrenergic nervous system, which could exert pro-apoptotic effects on
285 lymphocytes(Charach et al., 2011). Platelets were differentiated from the mononuclear-phagocyte
286 system and were the key mediator linking the two pathological processes of inflammation and
287 thrombosis(Ye et al., 2019). On the one hand, platelets were the main effector molecules for
288 hemostasis after cardiovascular injury. On the other hand, the activation of platelets plays a major
289 role in pathogenic thrombosis and participates in the pathogenesis of many groups of cardiovascular
290 diseases, including coronary heart disease(Glezeva et al., 2016). Moreover, Platelets interacted with
291 leukocytes and their subtypes (neutrophil, lymphocytes, etc.) and endothelial cells and activated
292 them, inducing monocyte adhesion and transport, releasing inflammatory factors such as TNF- α and
293 IL-1, which together promoted local inflammation and fibrosis in heart failure(Glezeva et al., 2016).
294 The study by Kandis(Kandis et al., 2011) et al. demonstrated that mean platelet volume (MPV),
295 indicating the activation of platelets, increased significantly in decompensated heart failure patients.
296 In addition, MPV at admission was independently associated with the hospital and 6-month
297 mortalities.

298 Besides, the subgroup analysis was also conducted, and the results demonstrated that the association
299 was stable and consistent between the high level of SII and the poor 30-day mortality across CHF
300 patients with different comorbidities or severity scores. We also noted that, among the critically ill
301 patients with CHF, patients complicated with AMI and hyperlipidemia had a higher risk of 30-day
302 mortality, and this risk was higher for higher SII, which implied that SII may be more valuable for
303 the prognostic evaluation of CHF patients with AMI or hyperlipidemia. Similarly, the previous study
304 has also shown that in patients with coronary heart disease, the high level of SII indicated a high risk
305 of cardiac death in the future, as well as the high incidence of non-fatal stroke and heart failure(Yang
306 et al., 2020). Although there was no research on the correlation between SII and hyperlipidemia, the
307 interconnection of hyperlipidemia and inflammation involved in the pathogenesis of cardiovascular
308 disease has been recognized(Rodriguez-Garcia and Alcaide, 2021).

309 As a retrospective cohort study, the existence of confounding factors cannot be ignored, and it was
310 difficult to intuitively and accurately judge the correlation between SII level and the prognosis of
311 CHF patients. Another highlight of this study was the use of PSM analysis to reduce the imbalance of
312 confounding factors across different groups. After PSM, the most baseline characteristics were well-
313 balanced between these two groups, except for the use of dialysis, the type of first ICU admission,
314 and the peripheral vascular diseases. More importantly, the conclusion that high levels of SII were
315 independently related to high short-term mortality remained stand before and after PSM, which
316 improved the reliability of SII as a prognostic marker of CHF.

317 But at the same time, there were certain limitations in this study. First, the present study was
318 conducted at a single center and did not validate the prognostic value of SII in a validation cohort.
319 Second, the clinical data were collected retrospectively from databases and it was difficult to ensure
320 that variables were evenly distributed across groups, although multiple regression models were
321 conducted to adjust for confounders and PSM analysis was used to minimize inter-group differences
322 in baseline characteristics. Third, some significant variables may be omissive due to the lack of data.
323 Last, this study was unable to determine the underlying mechanism of the association between high
324 SII and poor prognosis of CHF patients, and further experiments are necessary.

325 **5 Conclusion**

326 In summary, the high level of SII is closely related to the poor short-term prognosis in critically ill
327 patients with CHF, including 30- and 90-day and hospital all-cause mortalities, as well as the
328 occurrence of MACEs, and is expected to be a simple and effective prognostic evaluation indicator.

329 **6 Conflict of Interest**

330 All authors declare that there is no conflict of interest.

331 **7 Author Contributions**

332 Zaixin Yu and Lihuang Zha are the senior author who conceived and designed the study. Yiyang
333 Tang and Xiaofang Zeng collected and analyzed the clinical data. Yiyang Tang drafted the
334 manuscript. Yilu Feng and Qin Chen participated in the implementation of statistical methods in this
335 study and put forward constructive suggestions. Zhenghui Liu and Hui Luo reviewed the study and
336 participated in the interpretation of the results. All authors gave final approval of the version to be
337 published, and agree to be accountable for all aspects of the work.

338 **8 Funding**

339 Our study was supported by the National Natural Science Foundation of China (81873416), the Key
340 Research and Development Program of Hunan Province (2020SK2065) and Natural Science
341 Foundation Project of Hunan Province (2020JJ4634).

342 **9 Data availability**

343 Publicly available datasets were analyzed in this study. This data can be extracted from Monitoring in
344 Intensive Care Database III version 1.4 (MIMIC-III v.1.4) after passing on the required courses and
345 obtaining the authorization.

346 **Reference styles**

347 Agus, H.Z., Kahraman, S., Arslan, C., Yildirim, C., Erturk, M., Kalkan, A.K., et al. (2020). Systemic
348 immune-inflammation index predicts mortality in infective endocarditis. *J Saudi Heart Assoc*
349 32(1), 58-64. doi: 10.37616/2212-5043.1010.

350 Anker, S.D., and von Haehling, S. (2004). Inflammatory mediators in chronic heart failure: an
351 overview. *Heart* 90(4), 464-470. doi: 10.1136/hrt.2002.007005.

352 Arruda-Olson, A.M., Reeder, G.S., Bell, M.R., Weston, S.A., and Roger, V.L. (2009). Neutrophilia
353 predicts death and heart failure after myocardial infarction: a community-based study. *Circ*
354 *Cardiovasc Qual Outcomes* 2(6), 656-662. doi: 10.1161/CIRCOUTCOMES.108.831024.

355 Bonaventura, A., Montecucco, F., Dallegri, F., Carbone, F., Luscher, T.F., Camici, G.G., et al.
356 (2019). Novel findings in neutrophil biology and their impact on cardiovascular disease.
357 *Cardiovasc Res* 115(8), 1266-1285. doi: 10.1093/cvr/cvz084.

358 Bradham, W.S., Bozkurt, B., Gunasinghe, H., Mann, D., and Spinale, F.G. (2002). Tumor necrosis
359 factor-alpha and myocardial remodeling in progression of heart failure: a current perspective.
360 *Cardiovasc Res* 53(4), 822-830. doi: 10.1016/s0008-6363(01)00503-x.

361 Charach, G., Grosskopf, I., Roth, A., Afek, A., Wexler, D., Sheps, D., et al. (2011). Usefulness of
362 total lymphocyte count as predictor of outcome in patients with chronic heart failure. *Am J*
363 *Cardiol* 107(9), 1353-1356. doi: 10.1016/j.amjcard.2010.12.049.

364 Chen, J., Normand, S.L., Wang, Y., and Krumholz, H.M. (2011). National and regional trends in
365 heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. *JAMA*
366 306(15), 1669-1678. doi: 10.1001/jama.2011.1474.

367 Cho, J.H., Cho, H.J., Lee, H.Y., Ki, Y.J., Jeon, E.S., Hwang, K.K., et al. (2020). Neutrophil-
368 Lymphocyte Ratio in Patients with Acute Heart Failure Predicts In-Hospital and Long-Term
369 Mortality. *J Clin Med* 9(2). doi: 10.3390/jcm9020557.

370 Dick, S.A., and Epelman, S. (2016). Chronic Heart Failure and Inflammation: What Do We Really
371 Know? *Circ Res* 119(1), 159-176. doi: 10.1161/CIRCRESAHA.116.308030.

372 Glezeva, N., Gilmer, J.F., Watson, C.J., and Ledwidge, M. (2016). A Central Role for Monocyte-
373 Platelet Interactions in Heart Failure. *J Cardiovasc Pharmacol Ther* 21(3), 245-261. doi:
374 10.1177/1074248415609436.

375 Hu, B., Yang, X.R., Xu, Y., Sun, Y.F., Sun, C., Guo, W., et al. (2014). Systemic immune-
376 inflammation index predicts prognosis of patients after curative resection for hepatocellular
377 carcinoma. *Clin Cancer Res* 20(23), 6212-6222. doi: 10.1158/1078-0432.CCR-14-0442.

- 378 Jaddoe, V.W., de Jonge, L.L., Hofman, A., Franco, O.H., Steegers, E.A., and Gaillard, R. (2014).
379 First trimester fetal growth restriction and cardiovascular risk factors in school age children:
380 population based cohort study. *BMJ* 348, g14. doi: 10.1136/bmj.g14.
- 381 Johnson, A.E., Pollard, T.J., Shen, L., Lehman, L.W., Feng, M., Ghassemi, M., et al. (2016). MIMIC-
382 III, a freely accessible critical care database. *Sci Data* 3, 160035. doi: 10.1038/sdata.2016.35.
- 383 Kandis, H., Ozhan, H., Ordu, S., Erden, I., Caglar, O., Basar, C., et al. (2011). The prognostic value
384 of mean platelet volume in decompensated heart failure. *Emerg Med J* 28(7), 575-578. doi:
385 10.1136/emj.2009.088401.
- 386 Li, H., Chen, C., and Wang, D.W. (2021). Inflammatory Cytokines, Immune Cells, and Organ
387 Interactions in Heart Failure. *Front Physiol* 12, 695047. doi: 10.3389/fphys.2021.695047.
- 388 Li, W., Huang, A., Zhu, H., Liu, X., Huang, X., Huang, Y., et al. (2020). Gut microbiota-derived
389 trimethylamine N-oxide is associated with poor prognosis in patients with heart failure. *Med J*
390 *Aust* 213(8), 374-379. doi: 10.5694/mja2.50781.
- 391 Mann, D.L. (2015). Innate immunity and the failing heart: the cytokine hypothesis revisited. *Circ Res*
392 116(7), 1254-1268. doi: 10.1161/CIRCRESAHA.116.302317.
- 393 Markousis-Mavrogenis, G., Tromp, J., Ouwerkerk, W., Devalaraja, M., Anker, S.D., Cleland, J.G., et
394 al. (2019). The clinical significance of interleukin-6 in heart failure: results from the
395 BIOSAT-CHF study. *Eur J Heart Fail* 21(8), 965-973. doi: 10.1002/ejhf.1482.
- 396 Plenz, G., Song, Z.F., Tjan, T.D., Koenig, C., Baba, H.A., Erren, M., et al. (2001). Activation of the
397 cardiac interleukin-6 system in advanced heart failure. *Eur J Heart Fail* 3(4), 415-421. doi:
398 10.1016/s1388-9842(01)00137-4.
- 399 Povsic, T.J. (2018). Emerging Therapies for Congestive Heart Failure. *Clin Pharmacol Ther* 103(1),
400 77-87. doi: 10.1002/cpt.913.
- 401 Rauchhaus, M., Doehner, W., Francis, D.P., Davos, C., Kemp, M., Liebenthal, C., et al. (2000).
402 Plasma cytokine parameters and mortality in patients with chronic heart failure. *Circulation*
403 102(25), 3060-3067. doi: 10.1161/01.cir.102.25.3060.
- 404 Rodriguez-Garcia, M., and Alcaide, P. (2021). Vascular Inflammation and Hyperlipidemia: The
405 Neutrophil Within. *JACC Basic Transl Sci* 6(6), 524-526. doi: 10.1016/j.jacbts.2021.05.006.
- 406 Savarese, G., and Lund, L.H. (2017). Global Public Health Burden of Heart Failure. *Card Fail Rev*
407 3(1), 7-11. doi: 10.15420/cfr.2016:25:2.
- 408 Strassheim, D., Dempsey, E.C., Gerasimovskaya, E., Stenmark, K., and Karoor, V. (2019). Role of
409 Inflammatory Cell Subtypes in Heart Failure. *J Immunol Res* 2019, 2164017. doi:
410 10.1155/2019/2164017.
- 411 Sun, D., Zhang, F., Ma, T., Zhang, Y., and Liang, Z. (2020). Atorvastatin alleviates left ventricular
412 remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho
413 kinase signaling pathway. *Pharmacol Rep* 72(4), 903-911. doi: 10.1007/s43440-020-00085-3.
- 414 Swirski, F.K., and Nahrendorf, M. (2013). Leukocyte behavior in atherosclerosis, myocardial
415 infarction, and heart failure. *Science* 339(6116), 161-166. doi: 10.1126/science.1230719.
- 416 Tosu, A.R., Kalyoncuoglu, M., Biter, H.I., Cakal, S., Selcuk, M., Cinar, T., et al. (2021). Prognostic
417 Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and
418 Mortality in Severe Aortic Stenosis Patients after TAVI. *Medicina (Kaunas)* 57(6). doi:
419 10.3390/medicina57060588.

- 420 Uthamalingam, S., Patvardhan, E.A., Subramanian, S., Ahmed, W., Martin, W., Daley, M., et al.
421 (2011). Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in
422 acute decompensated heart failure. *Am J Cardiol* 107(3), 433-438. doi:
423 10.1016/j.amjcard.2010.09.039.
- 424 Vaduganathan, M., Ambrosy, A.P., Greene, S.J., Mentz, R.J., Subacius, H.P., Maggioni, A.P., et al.
425 (2012). Predictive value of low relative lymphocyte count in patients hospitalized for heart
426 failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail* 5(6),
427 750-758. doi: 10.1161/CIRCHEARTFAILURE.112.970525.
- 428 Wang, B.L., Tian, L., Gao, X.H., Ma, X.L., Wu, J., Zhang, C.Y., et al. (2016). Dynamic change of
429 the systemic immune inflammation index predicts the prognosis of patients with
430 hepatocellular carcinoma after curative resection. *Clin Chem Lab Med* 54(12), 1963-1969.
431 doi: 10.1515/cclm-2015-1191.
- 432 Xu, M., Zhang, L., Song, S., Pan, L., Muhammad Arslan, I., Chen, Y., et al. (2021). Hydrogen
433 sulfide: Recent progress and perspectives for the treatment of dermatological diseases. *J Adv
434 Res* 27, 11-17. doi: 10.1016/j.jare.2020.02.003.
- 435 Yang, Y.L., Wu, C.H., Hsu, P.F., Chen, S.C., Huang, S.S., Chan, W.L., et al. (2020). Systemic
436 immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery
437 disease. *Eur J Clin Invest* 50(5), e13230. doi: 10.1111/eci.13230.
- 438 Ye, G.L., Chen, Q., Chen, X., Liu, Y.Y., Yin, T.T., Meng, Q.H., et al. (2019). The prognostic role of
439 platelet-to-lymphocyte ratio in patients with acute heart failure: A cohort study. *Sci Rep* 9(1),
440 10639. doi: 10.1038/s41598-019-47143-2.

441

442

443

444

445

446

447

448

449


450

451

452


453

454 **Figure 1.** The non-linear curve fitting of the association between SII and 30- (A) and 90- (B) day all-
455 cause mortalities in critically ill patients with CHF after adjusting for age, gender, race, and other
456 potential variables. SII, systemic immune-inflammation index. CHF, congestive heart failure.




457

458 **Figure 2.** Kaplan-Meier survival curves showing the 30- (A) and 90- (B) day all-cause mortalities
459 stratified by SII tertile in critically ill patients with CHF. SII, systemic immune-inflammation index.
460 CHF, congestive heart failure.




461

462 **Figure 3.** The histogram presenting the range of propensity scores and the corresponding number of
463 matches in high (red) and low (blue) SII groups. SII, systemic immune-inflammation index.



464

465 **Figure 4.** Kaplan-Meier survival curves showing the 30- (A) and 90- (B) day all-cause mortalities
466 stratified by cut-off value of SII in critically ill patients with CHF before PSM. C and D presented the
467 correlation between SII and 30- and 90-day mortalities after PSM, separately. SII, systemic immune-
468 inflammation index. CHF, congestive heart failure. PSM, propensity score matching.




469

470 **Figure 5.** The forest plot showing the univariate (A) and multivariate (B) Cox regression for effects
471 of SII on short-term mortality in the critically ill patients with CHF before and after PSM. SII,
472 systemic immune-inflammation index. CHF, congestive heart failure. PSM, propensity score
473 matching.


A Univariate analysis

	p value	HR(95%CI)
Before PSM		
30-day mortality	<0.0001	1.8841(1.6145, 2.1986)
90-day mortality	<0.0001	1.7045(1.4893, 1.9508)
Hospital mortality	<0.0001	1.7299(1.4624, 2.0463)
After PSM		
30-day mortality	0.0014	1.4108(1.1416, 1.7435)
90-day mortality	0.0075	1.2829(1.0686, 1.5402)
Hospital mortality	0.0019	1.4352(1.1423, 1.8033)



B Multivariate analysis

	p value	HR(95%CI)
Before PSM		
30-day mortality	<0.0001	1.3930(1.1887, 1.6323)
90-day mortality	0.0003	1.2923(1.1254, 1.4840)
Hospital mortality	0.0004	1.3652(1.1486, 1.6226)
After PSM		
30-day mortality	0.0021	1.4018(1.1306, 1.7380)
90-day mortality	0.0068	1.2917(1.0730, 1.5550)
Hospital mortality	0.0167	1.3276(1.0526, 1.6745)



474
475
476
477
478
479
480
481
482

483 **Table 1.** The baseline clinical characteristics of critically ill patients with CHF.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	<i>p</i> value
Demographics				
Age, years	74.91 (64.06-83.07)	72.70 (61.97-81.65)	78.94 (69.40-84.82)	<0.001
Male, n (%)	2436 (52.89%)	1690 (52.39%)	746 (54.06%)	0.298
Ethnicity, n (%)				<0.001
White	3349 (72.71%)	2361 (73.19%)	988 (71.59%)	
Black	332 (7.21%)	254 (7.87%)	78 (5.65%)	
Others	925 (20.08%)	611 (18.94%)	314 (22.75%)	
Vital signs				
HR, beats/minute	85.02 (74.53-96.54)	84.33 (74.33-95.77)	86.67 (75.24-98.65)	<0.001
RR, times/minute	19.42 (16.87-22.38)	19.17 (16.76-21.91)	20.03 (17.24-23.45)	<0.001
SBP, mmHg	113.64 (104.46-125.96)	114.89 (105.50-126.98)	111.04 (101.60-123.48)	<0.001
DBP, mmHg	56.93 (50.87-63.71)	57.85 (51.64-64.34)	55.10 (49.46-61.64)	<0.001
Temperature, °C	36.76 (36.37-37.21)	36.80 (36.42-37.22)	36.65 (36.26-37.13)	<0.001
SpO ₂ , %	97.23 (95.74-98.46)	97.25 (95.81-98.49)	97.19 (95.52-98.40)	0.018
Weight, kg	77.75 (64.70-93.60)	79.80 (65.60-96.00)	73.80 (62.00-88.00)	<0.001
Therapies, n (%)				
ACEI	1266 (27.49%)	1012 (31.37%)	254 (18.41%)	<0.001
ARB	183 (3.97%)	151 (4.68%)	32 (2.32%)	<0.001
β-blocker	2827 (61.38%)	2074 (64.29%)	753 (54.57%)	<0.001
Digoxin	475 (10.31%)	303 (9.39%)	172 (12.46%)	0.002
Furosemide	3190 (69.26%)	2275 (70.52%)	915 (66.30%)	0.004
Statins	1451 (31.50%)	1121 (34.75%)	330 (23.91%)	<0.001
Dialysis	478 (10.38%)	278 (8.62%)	200 (14.49%)	<0.001
Vasopressor	1234 (26.79%)	727 (22.54%)	507 (36.74%)	<0.001
Ventilation	1879 (40.79%)	1133 (35.12%)	746 (54.06%)	<0.001
Assisted circulation	282 (6.12%)	186 (5.77%)	96 (6.96%)	0.123

484 **Table 1.** Continued.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	<i>p</i> value
Laboratory events				
Hemoglobin, g/dl	10.90 (9.70-12.30)	11.10 (9.80-12.50)	10.70 (9.40-11.90)	<0.001
Creatinine, mg/dl	1.20 (0.90-1.80)	1.20 (0.90-1.70)	1.30 (0.90-2.10)	<0.001
BUN, mg/dl	27.00 (18.00-43.00)	25.00 (17.00-40.00)	33.00 (21.00-51.00)	<0.001
Glucose, mg/dl	135.33 (115.00-166.12)	134.23 (115.47-164.03)	137.71 (114.36-170.52)	0.111
Sodium, mmol/L	139.00 (136.00-141.00)	139.00 (136.00-141.00)	138.00 (135.00-141.00)	0.023
Potassium, mmol/L	4.20 (3.80-4.60)	4.10 (3.70-4.60)	4.20 (3.80-4.70)	0.002
Chloride, mmol/L	103.00 (99.00-107.00)	103.00 (99.25-107.00)	103.00 (99.00-107.00)	0.035
Bicarbonate, mmol/L	24.00 (21.00-28.00)	25.00 (22.00-28.00)	24.00 (20.00-27.00)	<0.001
PT, second	14.30 (13.20-16.80)	14.20 (13.10-16.50)	14.80 (13.40-17.90)	<0.001
APTT, second	31.80 (27.30-40.40)	31.30 (27.10-40.20)	32.70 (27.87-41.10)	0.001
Lactate, mmol/L	1.82 (1.30-2.90)	1.80 (1.20-2.83)	2.00 (1.30-3.00)	<0.001
Albumin, g/dL	3.00 (2.56-3.40)	3.00 (2.60-3.42)	2.89 (2.45-3.24)	<0.001
Bilirubin, mg/dL	1.40 (0.60-3.05)	1.40 (0.60-3.00)	1.41 (0.60-3.10)	0.339
ALT, IU/L	60.00 (22.00-298.33)	69.00 (23.92-327.15)	45.00 (19.00-207.75)	<0.001
NT-proBNP, ng/ml	10.98 (4.67-18.83)	10.70 (4.26-18.34)	11.91 (5.67-19.96)	<0.001
cTnT, ng/mL	1.34 (0.10-2.87)	1.46 (0.11-2.94)	1.12 (0.09-2.58)	<0.001
CI, L/min/m ²	2.76 (2.13-3.47)	2.75 (2.13-3.48)	2.78 (2.14-3.45)	0.626
Urine output, L	1.54 (0.89-2.44)	1.73 (1.02-2.65)	1.14 (0.67-1.87)	<0.001
SII ×10	174.76 (92.24-344.55)	163.11 (88.62-309.02)	213.97 (105.80-430.34)	<0.001
Hospitalization type				<0.001
Emergency, n (%)	4062 (88.19%)	2804 (86.92%)	1258 (91.16%)	
Elective, n (%)	367 (7.97%)	300 (9.30%)	67 (4.86%)	
First ICU admission				<0.001
CCU, n (%)	1236 (26.83%)	898 (27.84%)	338 (24.49%)	
MICU, n (%)	2005 (43.53%)	1308 (40.55%)	697 (50.51%)	

485 **Table 1.** Continued.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	<i>p</i> value
Comorbidities, n (%)				
Hypertension	937 (20.34%)	655 (20.30%)	282 (20.43%)	0.919
Hyperlipemia	1260 (27.36%)	975 (30.22%)	285 (20.65%)	<0.001
Diabetes mellitus	1657 (35.97%)	1218 (37.76%)	439 (31.81%)	<0.001
Atrial fibrillation	2077 (45.09%)	1361 (42.19%)	716 (51.88%)	<0.001
AMI	346 (7.51%)	241 (7.47%)	105 (7.61%)	0.871
VHD	463 (10.05%)	289 (8.96%)	174 (12.61%)	<0.001
Peripheral vascular	577 (12.53%)	397 (12.31%)	180 (13.04%)	0.489
Pulmonary circulation	292 (6.34%)	183 (5.67%)	109 (7.90%)	0.005
Pneumonia	1350 (29.31%)	858 (26.60%)	492 (35.65%)	<0.001
COPD	245 (5.32%)	156 (4.84%)	89 (6.45%)	0.025
Liver diseases	232 (5.04%)	138 (4.28%)	94 (6.81%)	<0.001
Renal failure	1120 (24.32%)	757 (23.47%)	363 (26.30%)	0.040
Stroke	250 (5.43%)	148 (4.59%)	102 (7.39%)	<0.001
Hypothyroidism	555 (12.05%)	392 (12.15%)	163 (11.81%)	0.746
Malignancy	253 (5.49%)	128 (3.97%)	125 (9.06%)	<0.001
Depression	359 (7.79%)	276 (8.56%)	83 (6.01%)	0.003
Scores				
SOFA	5.00 (3.00-7.00)	4.00 (3.00-6.00)	6.00 (4.00-8.00)	<0.001
SAPSII	40.00 (32.00-49.00)	38.00 (30.00-46.00)	47.00 (39.00-56.00)	<0.001
Length of ICU stay, h	94.00 (50.00-187.00)	88.00 (48.00-166.75)	122.00 (62.00-240.25)	<0.001

486 Abbreviations: HR, heart rate; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic
 487 blood pressure; SpO₂, percutaneous oxygen saturation; ACEI, angiotensin-converting enzyme
 488 inhibitors; ARB, angiotensin receptor blockers; BUN, blood urea nitrogen; PT, prothrombin time;
 489 APTT, activated partial thromboplastin time; ALT, alanine transaminase; cTnT, troponin T; NT-
 490 proBNP, N-terminal pro brain natriuretic peptide; CI, cardiac index; SII, Systemic immune-
 491 inflammation index; CHF, congestive heart failure; AMI, acute myocardial infarction; VHD, valvular
 492 heart disease; COPD, chronic obstructive pulmonary disease. CCU, cardiac care unit; MICU, medical
 493 intensive care unit.

494 **Table 2.** The univariate and multivariate Cox regression analysis exploring the association of SII
 495 tertile with short-term mortality of critically ill patients with CHF.

	Crude		Model I		Model II	
	HR (95% CIs)	P value	HR (95% CIs)	P value	HR (95% CIs)	P value
30-day all-cause mortality						
SII	1.00 (1.00, 1.00)	<0.001	1.00 (1.00, 1.00)	<0.0001	1.00 (1.00, 1.00)	<0.0001
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.17 (0.99, 1.38)	0.067	1.14 (0.97, 1.35)	0.112	1.05 (0.89, 1.25)	0.524
≥2730.11	1.73 (1.48, 2.03)	<0.001	1.63 (1.40, 1.91)	<0.001	1.23 (1.04, 1.45)	0.011
P for trend	<0.001		<0.001		<0.001	
90-day all-cause mortality						
SII	1.00 (1.00, 1.00)	<0.001	1.00 (1.00, 1.00)	<0.0001	1.00 (1.00, 1.00)	0.001
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.12 (0.97, 1.28)	0.114	1.10 (0.96, 1.27)	0.168	1.02 (0.88, 1.17)	0.820
≥2730.11	1.65 (1.45, 1.88)	<0.001	1.57 (1.38, 1.79)	<0.001	1.21 (1.06, 1.39)	0.005
P for trend	<0.001		<0.001		<0.001	
Hospital all-cause mortality						
SII	1.00 (1.00, 1.00)	<0.001	1.00 (1.00, 1.00)	<0.0001	1.00 (1.00, 1.00)	0.002
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.27 (1.06, 1.52)	0.008	1.21 (1.01, 1.45)	0.035	1.17 (0.97, 1.40)	0.096
≥2730.11	1.61 (1.36, 1.91)	<0.001	1.45 (1.22, 1.72)	<0.001	1.26 (1.05, 1.50)	0.011
P for trend	<0.001		<0.001		<0.001	

496 Crude model was adjusted for none.

497 Model I was adjusted for age, gender, and race.

498 Model II was adjusted for age, gender, race, heart rate, blood urea nitrogen, albumin, troponin T, NT-
 499 proBNP, urine output of first day, cardiac index, the type of first ICU admission, the use of
 500 mechanical ventilation and vasopressor, pneumonia, and liver diseases.

501 Abbreviations: SII, Systemic immune-inflammation index; CHF, congestive heart failure; HR,
 502 hazard ratio; CI, confidence interval.

503 **Table 3.** The univariate and multivariate Logistic regression analysis exploring the association of SII
 504 tertile with readmission and MACEs of critically ill patients with CHF.

	Crude		Model I		Model II	
	OR (95% CIs)	P value	OR (95% CIs)	P value	OR (95% CIs)	P value
Readmission						
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	0.91 (0.77, 1.07)	0.253	0.94 (0.80, 1.11)	0.472	0.94 (0.80, 1.11)	0.484
≥2730.11	0.88 (0.75, 1.04)	0.129	0.93 (0.78, 1.10)	0.392	0.97 (0.81, 1.15)	0.703
P for trend	<0.001		<0.001		<0.001	
MACEs						
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.17 (1.02, 1.35)	0.030	1.17 (1.02, 1.35)	0.028	0.92 (0.74, 1.13)	0.417
≥2730.11	2.01 (1.73, 2.32)	<0.001	2.02 (1.74, 2.35)	<0.001	1.39 (1.12, 1.73)	0.003
P for trend	<0.001		<0.001		<0.001	

505 Crude model was adjusted for none.
 506 Model I was adjusted for age, gender, and race.
 507 Model II was adjusted for age, gender, race, heart rate, blood urea nitrogen, albumin, troponin T, NT-
 508 proBNP, urine output of first day, cardiac index, the type of first ICU admission, the use of
 509 mechanical ventilation and vasopressor, pneumonia, and liver diseases.
 510 Abbreviations: SII, Systemic immune-inflammation index; CHF, congestive heart failure; HR,
 511 hazard ratio; CI, confidence interval.

512

513

514

515

516

517

518

519

520 **Table 4.** Subgroup analysis of the relationship between SII and 30-day all-cause mortality.

	N	SII			P for interaction
		<1144.28	≥1144.28, <2730.11	≥2730.11	
Hypertension					0.178
No	3669	1.0 (ref)	1.09 (0.90, 1.31)	1.70 (1.44, 2.02)	
Yes	937	1.0 (ref)	1.57 (1.07, 2.31)	1.88 (1.28, 2.76)	
Diabetes					0.384
No	2949	1.0 (ref)	1.16 (0.95, 1.42)	1.62 (1.34, 1.95)	
Yes	1657	1.0 (ref)	1.22 (0.90, 1.65)	2.01 (1.52, 2.67)	
Hyperlipemia					0.006
No	3346	1.0 (ref)	1.13 (0.94, 1.36)	1.51 (1.27, 1.80)	
Yes	1260	1.0 (ref)	1.40 (0.96, 2.05)	2.77 (1.94, 3.96)	
AMI					0.016
No	4260	1.0 (ref)	1.09 (0.92, 1.30)	1.71 (1.46, 2.01)	
Yes	346	1.0 (ref)	2.63 (1.30, 5.30)	2.31 (1.14, 4.69)	
VHD					0.602
No	4143	1.0 (ref)	1.15 (0.96, 1.38)	1.76 (1.49, 2.07)	
Yes	463	1.0 (ref)	1.23 (0.76, 2.00)	1.50 (0.94, 2.41)	
PCD					0.931
No	4314	1.0 (ref)	1.17 (0.98, 1.39)	1.72 (1.46, 2.02)	
Yes	292	1.0 (ref)	1.15 (0.61, 2.19)	1.86 (1.05, 3.32)	
Atrial fibrillation					0.437
No	2529	1.0 (ref)	1.04 (0.82, 1.31)	1.59 (1.28, 1.98)	
Yes	2077	1.0 (ref)	1.29 (1.02, 1.64)	1.84 (1.47, 2.31)	
Pneumonia					0.061
No	3256	1.0 (ref)	1.18 (0.96, 1.44)	1.89 (1.56, 2.29)	
Yes	1350	1.0 (ref)	1.09 (0.82, 1.45)	1.33 (1.03, 1.74)	
COPD					0.962
No	4361	1.0 (ref)	1.16 (0.98, 1.38)	1.72 (1.47, 2.02)	
Yes	245	1.0 (ref)	1.32 (0.54, 3.20)	1.86 (0.83, 4.17)	
Liver diseases					0.065
No	4374	1.0 (ref)	1.26 (1.06, 1.50)	1.85 (1.57, 2.18)	
Yes	232	1.0 (ref)	0.62 (0.34, 1.13)	1.24 (0.70, 2.21)	

521 **Table 4.** Continued.

	N	SII			P for interaction
		<1144.28	≥1144.28, <2730.11	≥2730.11	
Renal failure					0.396
No	3486	1.0 (ref)	1.10 (0.91, 1.33)	1.72 (1.44, 2.05)	
Yes	1120	1.0 (ref)	1.39 (1.00, 1.94)	1.79 (1.30, 2.48)	
Hypothyroidism					0.628
No	4051	1.0 (ref)	1.13 (0.95, 1.35)	1.71 (1.45, 2.01)	
Yes	555	1.0 (ref)	1.46 (0.90, 2.38)	1.96 (1.23, 3.12)	
Stroke					0.618
No	4356	1.0 (ref)	1.14 (0.96, 1.36)	1.69 (1.44, 1.99)	
Yes	250	1.0 (ref)	1.45 (0.79, 2.65)	2.24 (1.26, 3.97)	
Depression					0.216
No	4247	1.0 (ref)	1.17 (0.98, 1.39)	1.79 (1.52, 2.10)	
Yes	359	1.0 (ref)	1.11 (0.55, 2.25)	1.02 (0.51, 2.03)	
Malignancy					0.879
No	4353	1.0 (ref)	1.18 (0.99, 1.40)	1.72 (1.46, 2.02)	
Yes	253	1.0 (ref)	1.02 (0.57, 1.83)	1.57 (0.94, 2.63)	
SOFA					0.172
<5	2149	1.0 (ref)	1.24 (0.91, 1.70)	2.21 (1.66, 2.96)	
≥5	2457	1.0 (ref)	1.20 (0.99, 1.46)	1.58 (1.31, 1.90)	
SAPSI					0.255
<40	2181	1.0 (ref)	1.22 (0.87, 1.71)	1.99 (1.43, 2.75)	
≥40	2425	1.0 (ref)	1.13 (0.93, 1.37)	1.42 (1.19, 1.69)	

522 Abbreviations: SII, Systemic immune-inflammation index; AMI, acute myocardial infarction; VHD,
 523 valvular heart disease; PCD, peripheral vascular diseases; COPD, chronic obstructive pulmonary
 524 disease.

525

526

527

528

529

530 **Table 5. The clinical characteristics in critically ill patients with CHF before and after PSM.**

Parameter	Before PSM			After PSM		
	<5533.4	≥5533.4	<i>P</i> value	<5533.4	≥5533.4	<i>P</i> value
N	3995	611		602	602	602
Demographics						
Age, years	74.4 (63.4-82.9)	76.9 (68.2-83.7)	<0.001	77.7 (66.1-84.2)	76.9 (68.1-83.7)	0.984
Male, n (%)	2154 (53.9%)	282 (46.2%)	<0.001	279 (46.3%)	279 (46.3%)	1.000
Ethnicity, n (%)		0.001	0.001			0.526
White	2879 (72.1%)	470 (76.9%)		463 (76.9%)	461 (76.6%)	
Black	309 (7.7%)	23 (3.8%)		30 (5.0%)	23 (3.8%)	
Others	807 (20.2%)	118 (19.3%)		109 (18.1%)	118 (19.6%)	
Vital signs						
HR, beats/minute	84.5 (74.1-96.0)	88.2 (77.0-99.6)	<0.001	87.5 (77.3-98.8)	87.9 (76.8-99.2)	0.840
RR, times/minute	19.3 (16.8-22.3)	20.3 (17.6-23.2)	<0.001	20.2 (17.3-23.5)	20.2 (17.6-23.1)	0.876
SBP, mmHg	113.8 (104.6-126.0)	113.8 (104.6-126.0)	0.145	113.9 (103.4-125.6)	112.1 (103.5-125.7)	0.964
DBP, mmHg	57.1 (51.1-63.9)	55.7 (50.2-62.5)	0.009	55.3 (49.1-61.9)	55.6 (50.2-62.5)	0.219
Temperature, °C	36.8 (36.4-37.2)	36.7 (36.3-37.1)	0.010	36.8 (36.4-37.2)	36.7 (36.3-37.1)	0.254
SpO ₂ , %	97.3 (95.8-98.5)	97.0 (95.5-98.4)	0.157	97.3 (95.6-98.5)	97.0 (95.5-98.4)	0.474
Weight, kg	78.4 (65.0-94.3)	74.4 (61.0-90.0)	<0.001	73.0 (61.0-88.5)	74.4 (61.0-90.0)	0.560
Therapies, n (%)						
ACEI	1117 (28.0%)	149 (24.4%)	0.065	153 (25.4%)	147 (24.4%)	0.689
ARB	158 (4.0%)	25 (4.1%)	0.872	26 (4.3%)	25 (4.2%)	0.886
β-blocker	2454 (61.4%)	373 (61.0%)	0.858	373 (62.0%)	367 (61.0%)	0.722
Digoxin	411 (10.3%)	64 (10.5%)	0.888	85 (14.1%)	63 (10.5%)	0.053
Furosemide	2766 (69.2%)	424 (69.4%)	0.937	412 (68.4%)	416 (69.1%)	0.804
Statins	1274 (31.9%)	177 (29.0%)	0.148	158 (26.2%)	174 (28.9%)	0.302
Dialysis	426 (10.7%)	52 (8.5%)	0.104	86 (14.3%)	51 (8.5%)	0.001
Vasopressor	1042 (26.1%)	192 (31.4%)	0.008	171 (28.4%)	187 (31.1%)	0.313
Ventilation	1561 (39.1%)	318 (52.0%)	<0.001	306 (50.8%)	310 (51.5%)	0.818
Assisted circulation	259 (6.5%)	23 (3.8%)	0.009	21 (3.5%)	23 (3.8%)	0.759
Scores						
SOFA	5.0 (3.0-7.0)	5.0 (3.0-7.0)	0.556	5.0 (3.0-7.0)	5.0 (3.0-7.0)	0.405
SAPSII	40.0 (32.0-49.0)	45.0 (36.0-53.5)	<0.001	44.0 (35.0-53.0)	45.0 (36.0-53.0)	0.440

531 **Table 5.** Continued.

Parameter	Before PSM			After PSM		
	<5533.4	≥5533.4	<i>P</i> value	<5533.4	≥5533.4	<i>P</i> value
N	3995	611		602	602	
Laboratory events						
Hemoglobin, g/dl	11.0 (9.7-12.4)	10.7 (9.5-12.1)	0.008	10.7 (9.5-11.9)	10.7 (9.5-12.1)	0.290
Creatinine, mg/dl	1.2 (0.9-1.8)	1.2 (0.9-2.1)	0.250	1.3 (0.9-2.0)	1.2 (0.9-2.1)	0.160
BUN, mg/dl	26.0 (18.0-42.0)	30.0 (19.0-49.0)	<0.001	31.0 (20.0-49.0)	30.0 (19.0-48.0)	0.613
Glucose, mg/dl	134.0 (114.4-163.6)	145.5 (119.7-176.8)	<0.001	141.2 (117.1-180.3)	145.5 (119.6-176.2)	0.610
Sodium, mmol/L	139.0 (136.0-141.0)	138.0 (135.0-141.0)	<0.001	138.0 (135.0-141.0)	138.0 (135.0-141.0)	0.487
Potassium, mmol/L	4.2 (3.8-4.6)	4.2 (3.7-4.7)	0.575	4.2 (3.8-4.7)	4.2 (3.7-4.7)	0.634
Chloride, mmol/L	103.0 (100.0-107.0)	102.0 (98.0-107.0)	<0.001	103.0 (99.0-106.0)	102.0 (98.0-107.0)	0.377
Bicarbonate, mmol/L	25.0 (21.0-28.0)	24.0 (20.0-27.0)	<0.001	24.0 (20.0-27.0)	24.0 (20.0-27.0)	0.878
PT, second	14.3 (13.2-16.8)	14.4 (13.2-17.1)	0.245	14.4 (13.2-17.3)	14.4 (13.2-17.2)	0.846
APTT, second	31.8 (27.3-41.1)	31.6 (27.3-38.6)	0.329	31.3 (27.3-40.2)	31.7 (27.3-38.7)	0.920
Lactate, mmol/L	1.9 (1.3-2.9)	1.8 (1.3-2.8)	0.654	1.8 (1.3-3.0)	1.8 (1.3-2.8)	0.654
Albumin, g/dL	3.0 (2.6-3.4)	2.9 (2.5-3.3)	<0.001	2.8 (2.4-3.3)	2.9 (2.5-3.3)	0.255
Bilirubin, mg/dL	1.5 (0.6-3.1)	0.9 (0.4-2.5)	<0.001	1.1 (0.5-2.4)	0.9 (0.4-2.6)	0.282
ALT, IU/L	62.0 (22.0-309.0)	50.0 (21.0-242.7)	0.034	51.0 (21.0-225.8)	50.0 (21.0-248.5)	0.637
NT-proBNP, ng/ml	10.9 (4.6-18.6)	12.1 (5.1-19.8)	0.019			
cTnT, ng/mL	1.4 (0.1-2.9)	1.1 (0.1-2.5)	0.016	1.1 (0.1-2.8)	1.1 (0.1-2.5)	0.768
CI, L/min/m ²	2.8 (2.1-3.5)	2.8 (2.2-3.5)	0.309	2.8 (2.1-3.4)	2.8 (2.2-3.5)	0.938
Urine output, L	1.6 (0.9-2.5)	1.4 (0.8-2.1)	<0.001	1.4 (0.7-2.2)	1.4 (0.8-2.1)	0.522
Hospitalization type			0.002			0.238
Emergency, n (%)	3498 (87.6%)	564 (92.3%)		538 (89.4%)	555 (92.2%)	
Elective, n (%)	338 (8.5%)	29 (4.7%)		39 (6.5%)	29 (4.8%)	
First ICU admission			<0.001			0.004
CCU, n (%)	1098 (27.5%)	138 (22.6%)		143 (23.8%)	138 (22.9%)	
Length of ICU stay, h	93.0 (50.0-184.0)	109.0 (54.0-204.0)	0.003	118.5 (59.0-228.8)	109.0 (53.0-201.8)	0.128
Comorbidities, n (%)						
Hypertension	830 (20.8%)	107 (17.5%)	0.062	126 (20.9%)	106 (17.6%)	0.144
Hyperlipemia	1120 (28.0%)	140 (22.9%)	0.008	133 (22.1%)	138 (22.9%)	0.730
Diabetes mellitus	1449 (36.3%)	208 (34.0%)	0.285	205 (34.1%)	205 (34.1%)	1.000

532 **Table 5.** Continued.

Parameter	Before PSM			After PSM		
	<5533.4	≥5533.4	<i>P</i> value	<5533.4	≥5533.4	<i>P</i> value
N	3995	611		602	602	
Comorbidities, n (%)						
Atrial fibrillation	1783 (44.6%)	294 (48.1%)	0.107	281 (46.7%)	290 (48.2%)	0.603
AMI	301 (7.5%)	45 (7.4%)	0.882	39 (6.5%)	44 (7.3%)	0.570
VHD	402 (10.1%)	61 (10.0%)	0.952	88 (14.6%)	61 (10.1%)	0.018
Peripheral vascular	511 (12.8%)	66 (10.8%)	0.167	88 (14.6%)	64 (10.6%)	0.037
Pulmonary circulation	239 (6.0%)	53 (8.7%)	0.011	45 (7.5%)	52 (8.6%)	0.459
Pneumonia	1108 (27.7%)	242 (39.6%)	<0.001	235 (39.0%)	237 (39.4%)	0.906
COPD	188 (4.7%)	57 (9.3%)	<0.001	48 (8.0%)	53 (8.8%)	0.603
Liver diseases	214 (5.4%)	18 (2.9%)	0.011	20 (3.3%)	18 (3.0%)	0.742
Renal failure	982 (24.6%)	138 (22.6%)	0.284	162 (26.9%)	136 (22.6%)	0.083
Stroke	227 (5.7%)	23 (3.8%)	0.051	38 (6.3%)	23 (3.8%)	0.052
Hypothyroidism	461 (11.5%)	94 (15.4%)	0.007	97 (16.1%)	92 (15.3%)	0.692
Malignancy	209 (5.2%)	44 (7.2%)	0.047	31 (5.1%)	43 (7.1%)	0.150
Depression	303 (7.6%)	56 (9.2%)	0.175	50 (8.3%)	56 (9.3%)	0.542
30-day mortality	769 (19.2%)	204 (33.4%)	<0.001	150 (24.9%)	200 (33.2%)	0.002
90-day mortality	1120 (28.0%)	260 (42.6%)	<0.001	211 (35.0%)	253 (42.0%)	0.013
Hospital-day mortality	659 (16.5%)	172 (28.2%)	<0.001	135 (22.4%)	167 (27.7%)	0.033

533 Abbreviations: PSM, propensity score matching; HR, heart rate; RR, respiratory rate; SBP, systolic
534 blood pressure; DBP, diastolic blood pressure; SpO₂, percutaneous oxygen saturation; ACEI,
535 angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BUN, blood urea
536 nitrogen; PT, prothrombin time; APTT, activated partial thromboplastin time; ALT, alanine
537 transaminase; cTnT, troponin T; NT-proBNP, N-terminal pro brain natriuretic peptide; CI, cardiac
538 index; SII, Systemic immune-inflammation index; CHF, congestive heart failure; AMI, acute
539 myocardial infarction; VHD, valvular heart disease; COPD, chronic obstructive pulmonary disease.
540 CCU, cardiac care unit.

541

542

543

544

545